Portal de investigación
Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Martinez-Arenas, L
- Carvalho-Gomes, A
- Berenguer, M
Grupos y Plataformas de I+D+i
Abstract
Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent chronic liver disease in Western countries, affecting approximately 25% of the adult population. This condition encompasses a spectrum of liver diseases characterized by abnormal accumulation of fat in liver tissue (non-alcoholic fatty liver, NAFL) that can progress to non-alcoholic steatohepatitis (NASH), characterized by the presence of liver inflammation and damage. The latter form often coexists with liver fibrosis which, in turn, may progress to a state of cirrhosis and, potentially, hepatocarcinoma, both irreversible processes that often lead to the patient's death and/or the need for liver transplantation. Along with the high associated economic burden, the high mortality rate among NAFLD patients raises interest, not only in the search for novel therapeutic approaches, but also in early diagnosis and prevention to reduce the incidence of NAFLD-related complications. In this line, an exhaustive characterization of the immune status of patients with NAFLD is mandatory. Herein, we attempted to gather and compare the current and relevant scientific evidence on this matter, mainly on human reports. We addressed the current knowledge related to circulating cellular and soluble mediators, particularly platelets, different leukocyte subsets and relevant inflammatory soluble mediators.
Datos de la publicación
- ISSN/ISSNe:
- 1661-6596, 1422-0067
- Tipo:
- Review
- Páginas:
- -
- DOI:
- 10.3390/ijms24032313
- PubMed:
- 36768637
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES MDPI AG
Citas Recibidas en Web of Science: 16
Documentos
Filiaciones
Keywords
- NAFLD; MAFLD; NAFL; NASH; steatosis; fibrosis; inflammation; platelets; leukocytes; biomarkers
Financiación
Proyectos y Estudios Clínicos
'Una aproximación translacional desde la clínica a la experimentación animal: Estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos. -
Investigador Principal: MARIA JESUS SANZ FERRANDO
PROMETEO2019/032 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO . 2020
CDEI-04/20-A GENT LAURA PIQUERAS (2019/200) CONTRATO
Investigador Principal: LAURA PIQUERAS RUIZ
2019/200C . CONSELLERIA DE SANIDAD
Modulación de la inflamación metabólica en la prevención de la patología cardiovascular: Identificación de nuevas dianas terapéuticas y desarrollo de herramientas farmacológicas novedosas (METINMUNOFAR).
Investigador Principal: MARIA JESUS SANZ FERRANDO
PID2020-120336RB-100 . MINISTERIO DE CIENCIA E INNOVACIÓN . 2021
Cita
Marques P,Francisco V,Martinez L,Carvalho A,Domingo E,Piqueras L,Berenguer M,Sanz MJ. Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2023. 24(3):2313. (1).
Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease. Marques,P, Francisco,V, Martinez Arenas,L, Carvalho Gomes,A, Domingo,E, Piqueras,L, Berenguer,M et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023 febrero 01. 24 (3):DOI:10.3390/ijms24032313. PMID:36768637.
